Radiation Doses and Cancer Risks from Breast Imaging Studies
Abstract
A single breast-specific gamma imaging or positron emission mammography study is associated with a fatal radiation-induced cancer risk higher than or comparable to that of annual screening mammography in women aged 40–80 years.
Purpose
To compare radiation doses and lifetime attributable risks (LARs) of radiation-induced cancer incidence and mortality from breast imaging studies involving the use of ionizing radiation.
Materials and Methods
Recent literature on radiation doses from radiologic procedures and organ doses from nuclear medicine procedures, along with Biologic Effects of Ionizing Radiation (BEIR) VII age-dependent risk data, is used to estimate LARs of radiation-induced cancer incidence and mortality from breast imaging studies involving ionizing radiation, including screen-film mammography, digital mammography, digital breast tomosynthesis, dedicated breast computed tomography, breast-specific gamma imaging (BSGI), and positron emission mammography (PEM).
Results
Two-view digital mammography and screen-film mammography involve average mean glandular radiation doses of 3.7 and 4.7 mGy, respectively. According to BEIR VII data, these studies are associated, respectively, with LARs of fatal breast cancer of 1.3 and 1.7 cases per 100 000 women aged 40 years at exposure and less than one case per one million women aged 80 years at exposure. Annual screening digital or screen-film mammography performed in women aged 40–80 years is associated with an LAR of fatal breast cancer of 20–25 cases in 100 000. A single BSGI study involving a label-recommended dose of 740–1100 MBq (20–30 mCi) of technetium 99m–sestamibi is estimated to involve an LAR of fatal cancer that is 20–30 times that of digital mammography in women aged 40 years. A single PEM study involving a labeled dose of 370 MBq (10 mCi) of fluorine 18 fluorodeoxyglucose is estimated to involve an LAR of fatal cancer that is 23 times higher than that of digital mammography in women aged 40 years.
Conclusion
A single BSGI or PEM study is associated with a fatal radiation-induced cancer risk higher than or comparable to that of annual screening mammography in women aged 40–80 years.
© RSNA, 2010
References
- 1 . Barriers to mammography screening in a managed care population. Public Adm Manage 2009;13(3):7–39.
- 2 ;
National Council on Radiation Protection and Measurements . National conference on dose reduction in CT, with an emphasis on pediatric patients. AJR Am J Roentgenol 2003;181(2):321–329. - 3 . Estimates of the cancer risks from pediatric CT radiation are not merely theoretical: comment on “point/counterpoint—in x-ray computed tomography, technique factors should be selected appropriate to patient size. against the proposition.” Med Phys 2001;28(11):2387–2388.
- 4 . Cancer risks attributable to low doses of ionizing radiation: assessing what we really know. Proc Natl Acad Sci U S A 2003;100(24):13761–13766.
- 5 . Computed tomography: an increasing source of radiation exposure. N Engl J Med 2007;357(22):2277–2284.
- 6 . Comparison of acquisition parameters and breast dose in digital mammography and screen-film mammography in the American College of Radiology Imaging Network Digital Mammographic Imaging Screening Trial. AJR Am J Roentgenol 2010;194(2):362–369.
- 7 . Dedicated breast CT: initial clinical experience. Radiology 2008;246(3):725–733.
- 8 . Digital breast tomosynthesis: initial experience in 98 women with abnormal digital screening mammography. AJR Am J Roentgenol 2007;189(3):616–623.
- 9 . Solid cancer incidence in atomic bomb survivors: 1958-1998. Radiat Res 2007;168(1):1–64.
- 10 . Studies of mortality of atomic bomb survivors: report 13—solid cancer and noncancer disease mortality: 1950-1997. Radiat Res 2003;160(4):381–407.
- 11 . Effect of recent changes in atomic bomb survivor dosimetry on cancer mortality risk estimates. Radiat Res 2004;162(4):377–389.
- 12 . Health risks from exposure to low levels of ionizing radiation: BEIR VII, phase 2—Committee to Assess Health Risks from Exposure to Low Levels of Ionizing Radiation. Washington, DC: National Academies Press, 2006.
- 13 . The 2007 recommendations of the International Commission on Radiological Protection. ICRP publication 103. Ann ICRP 2007;37(2-4):1–332.
- 14 . Recommendations of the International Commission on Radiological Protection. ICRP publication 26. Ann ICRP 1977;1(3):1–53.
- 15 . Risks associated with ionising radiations. ICRP publication SG1. Ann ICRP 1991;22(1):1–18.
- 16 . Radiation dose to organs and tissues from mammography: Monte Carlo and phantom study. Radiology 2008;246(2):434–443.
- 17 . Effective doses in radiology and diagnostic nuclear medicine: a catalog. Radiology 2008;248(1):254–263.
- 18 . Performance comparison of full-field digital mammography to screen-film mammography in clinical practice. Med Phys 2002;29(5):830–834.
- 19 . Radiologic and nuclear medicine studies in the United States and worldwide: frequency, radiation dose, and comparison with other radiation sources—1950–2007. Radiology 2009;253(2):520–531.
- 20 . Tomographic mammography using a limited number of low-dose cone-beam projection images. Med Phys 2003;30(3):365–380.
- 21 . Dedicated breast CT: radiation dose and image quality evaluation. Radiology 2001;221(3):657–667.
- 22 . Dedicated cone-beam breast CT: feasibility study with surgical mastectomy specimens. AJR Am J Roentgenol 2007;189(6):1312–1315.
- 23 . Doses from medical radiation sources. 2009 Health Physics Society Web site. http://www.hps.org/hpspublications/articles/dosesfrommedicalradiation.html.
Accessed May 6, 2010 . - 24 DePuey EGGarcia EVBerman DS, eds. Cardiac SPECT imaging. 2nd ed. Philadelphia, Pa: Lippincott Williams & Wilkins, 2000; 119–123.
- 25 Labeled organ doses for Miraluma (rest, 2 hour void). RxList Web site. http://www.rxlist.com/miraluma-drug.htm.
Accessed May 6, 2010 . - 26 . Whole-body PET/CT scanning: estimation of radiation dose and cancer risk. Radiology 2009;251(1):166–174.
- 27 . Composition of mammographic phantom materials. Radiology 1996;198(2):347–350.
- 28 . Performance benchmarks for screening mammography. Radiology 2006;241(1):55–66.
- 29 . Ionizing radiation exposure of the population of the United States. NCRP report no. 160. Bethesda, Md: National Council on Radiation Protection and Measurements, 2009.
- 30 . Quantitative assessment of mammographic breast density: relationship with breast cancer risk. Radiology 2004;230(1):29–41.
- 31 . Mammographic density and the risk and detection of breast cancer. N Engl J Med 2007;356(3):227–236.
- 32 . Informed consent and communication of risk from radiological and nuclear medicine examinations: how to escape from a communication inferno. BMJ 2004;329(7470):849–851.
- 33 . High-resolution fluorodeoxyglucose positron emission tomography with compression (“positron emission mammography”) is highly accurate in depicting primary breast cancer. Breast J 2006;12(4):309–323.
- 34 . Detection of ductal carcinoma in situ with mammography, breast specific gamma imaging, and magnetic resonance imaging: a comparative study. Acad Radiol 2007;14(8):945–950.
- 35 . Breast-specific gamma imaging as an adjunct imaging modality for the diagnosis of breast cancer. Radiology 2008;247(3):651–657.
- 36 . Invasive lobular carcinoma: detection with mammography, sonography, MRI, and breast-specific gamma imaging. AJR Am J Roentgenol 2009;192(2):379–383.
Article History
Received March 17, 2010; revision requested April 19; revision received May 6; accepted May 14; final version accepted May 19.Published online: Oct 2010
Published in print: Oct 2010